OQRO

Daily notes / October 16, 2026

PVG Asset Management reported 8.3% ownership of Retension Pharmaceuticals

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of . Published . 2 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers.
Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

PVG ASSET MANAGEMENT CORP filed a SCHEDULE 13G on Oct 16, 2026, reporting 1,002,050 shares, 8.3% of the class of Retension Pharmaceuticals (RTSN). The filing is an ownership disclosure, not a trade report, and does not state when the shares were bought. Other ownership filings, a Form 8-K, press coverage and share-price data are also on record around the filing date.

What did PVG Asset Management report?

The SEC Schedule 13G records that PVG ASSET MANAGEMENT CORP reported 1,002,050 shares, 8.3% of the class of Retension Pharmaceuticals (RTSN), on Oct 16, 2026.

A Schedule 13G is an ownership filing, not a trade report. It does not say when the shares were bought.

What other ownership filings are on record?

Schedule 13D and 13G filings on Retension Pharmaceuticals in the 180 days to Oct 16, 2026 include The B Group, Inc., which reported 10% of RTSN as a passive investor in a filing dated Oct 16, 2026. Laurence W. Lytton reported 7.4% of RTSN as a passive investor in a filing dated Oct 15, 2026.

These are separate ownership filings. The pack does not say when shares in those filings were bought.

What did the company report in its Form 8-K?

Retension Pharmaceuticals filed a Form 8-K of Oct 13, 2026, Item 5.03, 4 days after. OQRO classes the filing as reporting a change to its bylaws, charter or fiscal year.

The Form 8-K records what the company reported. It does not state what the report means for the share price.

What press coverage and share prices are listed?

Finnhub lists the headline “Retension Pharmaceuticals Announces Pricing of Initial Public Offering,” published by Yahoo on Oct 9, 2026. The Yahoo, Oct 9, 2026 item is listed as published by the outlet; OQRO has not checked it or summarized the article.

RTSN closed at $10.53 on Oct 9, 2026, the last session on or before the filing date. From Oct 9, 2026 to Oct 16, 2026, the close moved from $10.53 to $14.07, a change of +33.6%. The Retension Pharmaceuticals on OQRO page is also listed.

What this does not tell you?

The Schedule 13D or 13G is an ownership filing, not a trade; it does not say when shares were bought. The filing does not explain the share-price move, and other news can move a price.

An 8-K item says what the company reported, not what it means for the share price. Headlines are listed as published by the outlets; OQRO has not checked them and does not summarize articles. This describes public filings. It is not investment advice.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data

Explore the data

More daily notes